Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.550
-0.170 (-4.57%)
At close: Mar 28, 2025, 4:00 PM
3.749
+0.199 (5.61%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Lantern Pharma Employees
Lantern Pharma had 21 employees as of December 31, 2023. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
n/a
Profits / Employee
-$989,582
Market Cap
38.29M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LTRN News
- 3 days ago - Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - Business Wire
- 10 days ago - Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - Business Wire
- 5 weeks ago - Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates - Business Wire
- 2 months ago - Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer - Business Wire
- 3 months ago - Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
- 4 months ago - Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Business Wire
- 4 months ago - Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire